Shuji Inada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuji Inada has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hitoshi Tanimukai
Department of Psychiatric and Mental Health Nursing, Nagoya City University , 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
2 shared publications - Ryoichi Sadahiro
National Cancer Center Hospital Tokyo Japan
2 shared publications - Saho Wada
Division of Quality Assurance Programs, National Cancer Center Institute for Cancer Control , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
2 shared publications - Takaaki Hasegawa
Center for Psycho-oncology and Palliative Care, Nagoya City University Hospital, Nagoya, Japan
2 shared publications - Toru Okuyama
Nagoya City University Hospital
2 shared publications - Yoshiaki Okamoto
Faculty of Nursing Science, Tsuruga Nursing University , 78-2-1 Kizaki, Tsuruga, Fukui 914-0814
2 shared publications
Latest Publications
- 21 September 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations
Background: The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations. Methods: These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated. Results: Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients. Conclusions: These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.
- 21 September 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
The 2025 revision of JPOS/JASCC clinical guidelines for delirium in adult patients with cancer: a summary of recommendations
Background: The Japan Psycho-Oncology Society and the Japanese Association of Supportive Care in Cancer revised the clinical practice guidelines for delirium in adult patients with cancer in 2025. In this article, we describe the guideline revision and summarize the updated recommendations. Methods: These guidelines were developed in accordance with the Minds Manual for Clinical Practice Guideline Development 2020. The multidisciplinary guideline development group formulated four new clinical questions (CQs) addressing delirium prevention (ramelteon and orexin receptor antagonists) and management (combination therapies of antipsychotics with either benzodiazepines or antihistamines). In addition, systematic reviews of 11 existing CQs were updated. Results: Multicomponent interventions were strongly recommended for delirium prevention, based on moderate-certainty evidence. Bright light therapy, antipsychotics, ramelteon, and orexin receptor antagonists were not recommended for prevention. For delirium management, antipsychotics, trazodone, the combination of antipsychotics and benzodiazepines, and opioid switching were suggested, whereas hydroxyzine, benzodiazepines alone, and the combination of antipsychotics and antihistamines were not recommended. All recommendations for delirium management were weak, with low- to very-low-certainty evidence. Background questions addressed delirium assessment tools, precipitating factors, non-pharmacological interventions, and interventions for terminally ill patients. Conclusions: These revised clinical practice guidelines can serve as a practical framework for optimizing prevention, assessment, and management of delirium in adult patients with cancer in Japan.
- 7 October 2025
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 67 (1) , 35-47
Quality Indicators in Psychological Care for Patients With Serious Illness: A Systematic Review
- 7 October 2025
- Published by Elsevier in Journal of the Academy of Consultation-Liaison Psychiatry
- Vol. 67 (1) , 35-47
Quality Indicators in Psychological Care for Patients With Serious Illness: A Systematic Review